Platelet growth factors: potential impact on transfusion medicine
- 1 March 1999
- journal article
- review article
- Published by Wiley in Transfusion
- Vol. 39 (3) , 321-332
- https://doi.org/10.1046/j.1537-2995.1999.39399219292.x
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural CytokineScience, 1997
- Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancerPublished by Elsevier ,1996
- Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin.The Journal of Experimental Medicine, 1996
- Collection and transfusion of blood and blood components in the United States, 1992Transfusion, 1995
- Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligandNature, 1994
- Controversies in transfusion medicineTransfusion, 1992
- Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemiaThe Lancet, 1991
- A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitorsCell, 1990
- Bleeding Due to Thrombocytopenia in Acute Leukemias and Reevaluation of the Prophylactic Platelet Transfusion PolicyThe Lancet Healthy Longevity, 1986
- Demonstration and Some Properties of Human Thrombopoietin in Thrombocythaemic SeraActa Haematologica, 1958